Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 3/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM6 | O15303 | 1/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82826 | 0.77 | KDM5A (0.37) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL10901126 | 0.72 | LMNA (0.43) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL6037818 | 0.72 | FOLH1 (0.47) | FOLH1 | |
| SCHEMBL7608860 | 0.71 | FOLH1 (0.55) | FOLH1 | |
| SCHEMBL23881966 | 0.69 | METAP1 (0.49) | METAP1FOLH1 | |
| SCHEMBL2954900 | 0.69 | METAP1 (0.47) | METAP1ALOX5 | |
| SCHEMBL3382689 | 0.68 | CYP1A2 (0.41) | DPP4DPP9GRM8GRM6GRM7 | |
| SCHEMBL81045 | 0.68 | CYP1A2 (0.41) | DPP4DPP9GRM8GRM6GRM7 | |
| SCHEMBL23881965 | 0.68 | METAP1 (0.46) | GRM8GRM6GRM7GRM4METAP1 | |
| SCHEMBL5057914 | 0.67 | GRM3 (0.63) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183231-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-22 | — | — | US | claimed |
| JP-4813469-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| JP-2008503448-A | — | — | 2008-02-07 | — | — | JP | claimed |
| EP-1765850-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | Aventis Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | claimed |
| WO-2005118618-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-15 | — | — | WO | claimed |
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8183231-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1765850-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | Aventis Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2005118618-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | KDM5A 3791/4885PHF8 2063/4885KDM2A 3487/4885 |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | KDM5A 3791/4885PHF8 2063/4885KDM2A 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.